277 Pulmo HPN Flashcards
First prostanoid available for PAH that improves survival and functional capacity
Epoprostenol
Soluble guanylyl cyclase stimulator acting synergistically with endogenous NO improving exercise capacity and pulmonary hemodynamics
Riociguate
WHO Group. For pulmonary arterial hypertension
WHO Group 1
WHO Group. Pulmonary hypertension associated with left heart disease
WHO Group 2
WHO Group. Pulmonary hypertension associated with lung disease
WHO Group 3
WHO Group. Pulmonary hypertension associated with chronic thromboembolic disease
WHO Group 4
Important initial screening for pulmonary hypertension
Echocardiography with bubble study
Gold standard in establishing diagnosis of PH and guide to selection of appropriate medical therapy
Right heart catheterization with pulmonary vasodilator testing
Asthmatic but controlled. PE revealed accentuated O2 component of the second heart sound, right sided S3 or S4 and a holosystolic tricuspid regurgitant murmur. What diagnostic test?
Right heart catheterization
Hallmark of Group II PH
Elevated left atrial pressure with resulting pulmonary venous hypertension
Second most common cause of pulmonary hypertension
Intrinsic lung disease
Dominant factor in CTEPH Group IV
Obstruction of the proximal pulmonary vasculature
Treatment of PAH to improve composite endpoint of delay of clinical worsening
Macitentan (Endotheli receptor antagonist)
Selexipeg (Selective IP receptor agonist)
Iloprost (Prostacyclin derivative)
SIM
spectrum of diseases involving the pulmonary vasculature defined as elevated of pulmonary artery pressure
Pulmonary hypertension
what is the mean pulmonary artery pressure to say there is pulmonary hypertension
Mean pulmonary artery pressure more than 22 mmHg
